ChemoTech signs Memorandum of Understanding

Report this content

Today Tuesday 19th of June 2018 ChemoTech has signed a Memorandum of Understanding with Pusat Perubatan Universiti Malaya (PPUM) regarding the performance of a clinical study where patients with larger lesions are treated with the IQWave™ D-EECT (Dynamic-ElectroEnhanced Chemotherapy™).

The aim of this clinical study is to demonstrate a probable reduction of tumor size(s) and level of pain as well as improvement of life, when patients with cutaneous and subcutaneous head and neck tumors are treated with IQWave™ D-EECT. PPUM has already received “Special Access” for IQWave™ from the authorities, which is an import license for equipment or drugs that are not yet registered in the country.

PPUM is formerly known as ‘University Hospital’ is a government-funded medical institution located in Pantai Dalam, southwest corner of Kuala Lumpur, the dynamic and bustling capital city of Malaysia. It was established by Statute in September 1962 and is part of University of Malaya. The objectives of PPUM are to establish, operate and develop a medical centre of international standard and repute; and to co-operate with Faculty in providing facilities for medical education, training, research, internship and consultancy.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

Scandinavian ChemoTech AB (publ)

ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.